CONX Corp. Announces Closing of Initial Business Combination PR Newswire LITTLETON, Colo., May 1, 2024 LITTLETON, Colo., May 1, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or...
CONX Corp. Announces Final Tender Offer Results PR Newswire LITTLETON, Colo., April 29, 2024 LITTLETON, Colo., April 29, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the "Company" or "CONX...
CONX Corp. Announces Change in Tender Offer Price to Complete Business Combination PR Newswire LITTLETON, Colo., April 15, 2024 LITTLETON, Colo., April 15, 2024 /PRNewswire/ -- CONX Corp...
CONX Corp. Announces Tender Offer to Complete Business Combination PR Newswire LITTLETON, Colo., April 1, 2024 LITTLETON, Colo., April 1, 2024 /PRNewswire/ -- CONX Corp. (Nasdaq: CONX) (the...
CONX Files Proxy Statement for Stockholders to Vote on Extension of Completion Period; Discloses Preliminary Discussions Regarding Business Combination PR Newswire LITTLETON, Colo., Oct. 12, 2022...
-- Net loss for the quarter decreases 69% vs. prior year -- DENVER, Feb. 11 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide developer and...
New study will focus on identification of novel B-cell epitopes on Lassa virus proteins that could result in novel agents to treat and prevent the disease DENVER and NEW ORLEANS, Feb. 8...
DENVER, Feb. 2 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on...
Corgenix to manufacture BG Medicine's novel biomarker test in microtiter ELISA format DENVER, Dec. 14 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a...
DENVER, Nov. 12 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, today reported sales of...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約